- Tytuł:
- The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
- Autorzy:
- Żołnierek, Jakub
- Powiązania:
- https://bibliotekanauki.pl/articles/22792533.pdf
- Data publikacji:
- 2023-08-19
- Wydawca:
- Medical Education
- Tematy:
-
renal cell carcinoma
intermediate risk group
unfavourable risk group
tyrosine kinases inhibitor
immune check-point inhibitor - Opis:
- The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 - with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOr inhibitor necessitates a choice between two-drug immunotherapy or an antian giogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.
- Źródło:
-
OncoReview; 2023, 13, 2; 48-57
2450-6125 - Pojawia się w:
- OncoReview
- Dostawca treści:
- Biblioteka Nauki
Artykuł